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ABSTRACT
Staphylococcus aureus is a potentially pathogenic bacterium that causes a broad spectrum of diseases.
S. aureus can adapt rapidly to the selective pressure of antibiotics, and this has resulted in the emergence
and spread of methicillin-resistant S. aureus (MRSA). Resistance to methicillin and other b-lactam
antibiotics is caused by the mecA gene, which is situated on a mobile genetic element, the Staphylococcal
Cassette Chromosome mec (SCCmec). To date, ﬁve SCCmec types (I–V) have been distinguished, and
several variants of these SCCmec types have been described. All SCCmec elements carry genes for
resistance to b-lactam antibiotics, as well as genes for the regulation of expression of mecA. Additionally,
SCCmec types II and III carry non-b-lactam antibiotic resistance genes on integrated plasmids and a
transposon. The epidemiology of MRSA has been investigated by pulsed-ﬁeld gel electrophoresis
(PFGE), multilocus sequence typing (MLST), spa typing and SCCmec typing. Numerous MRSA clones
have emerged and disseminated worldwide. SCCmec has been acquired on at least 20 occasions by
different lineages of methicillin-sensitive S. aureus. Although most MRSA strains are hospital-acquired
(HA-MRSA), community-acquired MRSA (CA-MRSA) strains have now been recognised. CA-MRSA is
both phenotypically and genotypically different from HA-MRSA. CA-MRSA harbours SCCmec types IV
or V, and is associated with the genes encoding Panton–Valentine leukocidin. The prevalence of MRSA
ranges from 0.6% in The Netherlands to 66.8% in Japan. This review describes the latest developments
in knowledge concerning the structure of SCCmec, the molecular evolution of MRSA, the methods used
to investigate the epidemiology of MRSA, and the risk-factors associated with CA-MRSA and HA-
MRSA.
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INTRODUCTION
Since its discovery during the 1880s, Staphylococ-
cus aureus has emerged as a potentially patho-
genic Gram-positive bacterium that can cause
various diseases, ranging from minor infections of
the skin to post-operative wound infections,
bacteraemia, infections associated with foreign
bodies and necrotising pneumonia. Until the
introduction of penicillin, the mortality rate of
patients infected with S. aureus was c. 80%. In the
early 1940s, S. aureus infections were treated with
penicillin, but the ﬁrst strains resistant to this
antibiotic were isolated in 1942, ﬁrst in hospitals,
and later in the community. This resistance
resulted from the acquisition of a plasmid that
encoded a penicillin-hydrolysing enzyme, i.e.,
penicillinase. Since 1960, c. 80% of all S. aureus
isolates have been resistant to penicillin. In
addition, S. aureus strains have developed resist-
ance to methicillin and vancomycin through the
acquisition of the mecA and vanA genes, respect-
ively [1,2].
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STAPHYLOCOCCAL CASSETTE
CHROMOSOME mec (SCCmec )
The resistance of S. aureus to methicillin is caused
by the presence of the mecA gene, which encodes
the 78-kDa penicillin-binding protein (PBP) 2a (or
PBP2¢). b-Lactam antibiotics normally bind to
PBPs in the cell wall, resulting in the disruption of
synthesis of the peptidoglycan layer and death of
the bacterium. Since b-lactam antibiotics cannot
bind to PBP2a, synthesis of the peptidoglycan
layer and cell wall synthesis are able to continue.
The mecA gene is regulated by the repressor MecI
and the trans-membrane b-lactam-sensing signal-
transducer MecRI, both of which are transcribed
divergently. However, in the absence of a b-
lactam antibiotic, MecI represses the transcription
of both mecA and mecRI–mecI. In the presence of a
b-lactam antibiotic, MecRI is cleaved autocatalyt-
ically, and a metallo-protease domain, which is
located in the cytoplasmic part of MecRI, becomes
active. The metallo-protease cleaves MecI bound
to the operator region of mecA, which allows
transcription of mecA and subsequent production
of PBP2a [3]. Both mecI and mecRI can be trun-
cated by insertion sequences IS431 or IS1272, and
this results in derepression of the mecA gene [4].
The 2.1-kb mecA gene is located on a mobile
genetic element, designated the Staphylococcal
Cassette Chromosome mec (SCCmec) [5]. Cur-
rently, ﬁve main types of SCCmec (types I–V) have
been distinguished, ranging in size from 20.9 to
66.9 kb (Fig. 1). SCCmec types I (34.3 kb), IV
(20.9–24.3 kb) and V (28 kb) encode exclusively
for resistance to b-lactam antibiotics. In contrast,
SCCmec types II (53.0 kb) and III (66.9 kb) deter-
mine multiresistance, as these cassettes contain
additional drug resistance genes on integrated
plasmids (pUB110, pI258 and pT181) and a
transposon (Tn554). Plasmid pUB110 carries the
ant(4¢) gene, responsible for resistance to kana-
mycin, tobramycin and bleomycin, and pI258
codes for resistance to penicillins and heavy
metals. Plasmid pT181 codes for tetracycline
resistance, while transposon Tn554 carries the
ermA gene, which is responsible for inducible
macrolide, lincosamide and streptogramin resist-
ance (Fig. 1) [5,6]. Besides the resistance genes on
SCCmec, S. aureus can carry resistance genes
inserted at other sites of the chromosome and
on plasmids. SCCmec also carries insertion se-
quences, e.g., IS431, as well as genes responsible
for the regulation of mecA transcription, i.e.,
DmecRI (on SCCmec types I, IV and V) or mecRI
and mecI (on SCCmec types II and III) [5,7–9].
These genes are situated in mec complexes. To
date, ﬁve major classes, A–E, of mec complexes
have been distinguished (Table 1) [4,5,7].
For integration into and excision from the
chromosome at a speciﬁc site (attBscc; at the 3¢-
end of an open reading frame of unknown
function, termed orfX [10]), genes encoding cas-
sette chromosome recombinases (ccr) are located
within the SCCmec elements. These genes are
designated ccrA1 and ccrB1 (in SCCmec type I),
ccrA2 and ccrB2 (in SCCmec types II and IV), ccrA3
and ccrB3 (in SCCmec type III), ccrA4 and ccrB4 (in
SCCmec type IV of methicillin-resistant Staphylo-
coccus aureus (MRSA) strain HDE288) and ccrC (in
SCCmec type V). The regions bordering the mec
Fig. 1. Schematic arrangement of SCCmec types I–V [7–9,131]. The major elements of the ﬁve SCCmec types (ccr genes,
IS431, IS1272, mecA, mecI ⁄RI, orfX, pI258, pT181, pUB101 and Tn554) are shown, as are the six loci (A–F) used for SCCmec
typing according to the method of Oliviera et al. [17].
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and ccr complexes are designated the J (junkyard)
regions (Fig. 1) [4,8,9,11,12].
All SCCmec elements are divided into three
regions. The J1 region ranges from the chromo-
some right junction to the ccr genes, while the J2
region ranges from the ccr genes to the mec
complex. The J3 region is located between the mec
complex and the left extremity of SCCmec [13,14].
In addition to the ﬁve main SCCmec types, several
variants of SCCmec have been described (Table 2)
[5,12,13,15–19].
Besides MRSA, methicillin-resistant coagulase-
negative staphylococci can harbour SCCmec. It
has been shown that methicillin-resistant Staphy-
lococcus epidermidis isolates from the 1970s har-
boured SCCmec types I–IV [20]. Investigations of
the SCCmec type among 106 methicillin-resistant
Staphylococcus epidermidis isolates from the late
1990s identiﬁed SCCmec types I–V among 85
isolates, but the SCCmec type of the other 21
isolates could not be determined [21]. Hanssen
et al. [22] studied 39 methicillin-resistant coagu-
lase-negative staphylococcal isolates, of which 22
had a novel SCCmec type. Moreover, other studies
have found novel SCCmec types [13,23,24], or SCC
elements without mecA, which could be a reser-
voir for antibiotic resistance islands, in S. aureus
[25,26].
THE HISTORY OF MRSA
The ﬁrst MRSA strain (NCTC 10442), isolated
during 1961 in the UK, harboured SCCmec type I,
and this so-called archaic clone spread around the
world during the 1960s. In 1982, an MRSA strain
(N315) with SCCmec type II was discovered in
Japan, and this New York ⁄ Japan clone also
spread worldwide; this was followed by the
discovery in 1985 of an MRSA strain (85 ⁄ 2082)
harbouring SCCmec type III in New Zealand.
MRSA strains harbouring SCCmec IV spread
round the world during the 1990s, and at the
beginning of the 21st century, the ﬁrst MRSA
strain (WIS) with SCCmec type V was described in
Australia [8,24,27].
Although the origin of SCCmec remains un-
known, the cassette could originate from staphy-
lococci other than S. aureus. It is believed that
Staphylococcus sciuri harboured the ancestor of
PBP2a, since a PBP was found in S. sciuri that
showed 87.8% amino-acid sequence identity with
Table 1. Major classes of mec complexes
Class Structure SCCmec Species
A mecI–mecRI–mecA–IS431 II, III Staphylococcus aureus
B IS1272–DmecRI–mecA–IS431 I, IV S. aureus
C IS431–DmecRI–mecA–IS431 V S. aureus
D DmecRI–mecA–IS431 – Staphylococcus caprae
E DmecRI–mecA–IS431a – S. aureus
a976-bp deletion in mecRI compared to the class D mec complex.
Table 2. Structural variants of
SCCmec types I–VSCCmec Structure compared to main SCCmec type
Proposed novel
nomenclature [14]
IA pUB110 integrated downstream of mecA 1B.1.2
IIA SCCmec type IVb J1 region; class A4 mec complexa 2A.3.1
IIB SCCmec type IVb J1 region; lacks Tn554 2A.3.2
IIC SCCmec type IVb J1 region; class A3 mec complexb;
lacks ORFs between Tn554 and mec complex
2A.3.3
IID SCCmec type IVb J1 region; class A4 mec complexa;
lacks pUB110 and IS431 at left junction of SCCmec
2A.3.4
IIE SCCmec type IVb J1 region; class A3 mec complexb;
lacks region between Tn554 and mec complex;
lacks region between pUB110 and IS431
at left junction of SCCmec
2A.3.5
IIb Lacks pUB110; IS256 inserted upstream of mecI 2A.2
IIIA Lacks pT181 and its associated IS431 sequences 3C12
IIIB Lacks pT181 and pI258, together with IS431; lacks Tn554 3C13
IVa ⁄ IVb Different J1 regions when compared to SCCmec type IV;
harbours downstream constant region (dcs)
2B.1 ⁄ 2B.2.1
IVc Different J1 region compared to SCCmec type IV;
harbours Tn4001 ﬂanked by IS256 sequences
2B.3.1
IVd Different J1 region compared to SCCmec type IV 2B.4
IVA Harbours pUB110 downstream of mecA 2B.N.2
IVE Variant of SCCmec type IVc; lacks dcs region; different J3 region 2B.3.3
IVF Variant of SCCmec type IVd; lacks dcs region; different J3 region 2B.2.2
IVg Different J1 region composed of 5 ORFs compared to SCCmec type IV 2B.5
VT Harbours ccrC2 variant of ccrC 5C.2
amec complex A4, DmecI–IS1182–DmecI–mecRI–mecA.
bmec complex A3, IS1182–DmecI–mecRI–mecA.
ORF, open reading frame.
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PBP2a. These strains were all susceptible to
methicillin, but became resistant to methicillin
following growth of the strains in the presence of
methicillin because of an increase in the tran-
scription rate of the mecA homologue, subsequent
to a point mutation in the promoter. Furthermore,
a strain of methicillin-sensitive S. aureus (MSSA)
became resistant to methicillin following intro-
duction of this mecA homologue, and could thus
be classiﬁed as MRSA [28]. It has also been
reported that an epidemic MSSA strain and,
subsequently, an isogenic MRSA strain were
isolated from a neonate who had never been in
contact with MRSA. The mecA gene was identical
to that found in a S. epidermidis isolate from the
same patient. It was concluded that the MRSA
strain had emerged in vivo following horizontal
transfer of mecA between the two staphylococcal
species [29].
MOLECULAR TYPING OF MRSA
Strategies aimed at preventing the spread of
MRSA require a thorough knowledge of both
the dissemination and the epidemiology of MRSA
strains. For this purpose, various molecular typ-
ing techniques have been developed. These tech-
niques include pulsed-ﬁeld gel electrophoresis
(PFGE), multilocus sequence typing (MLST),
SCCmec typing, and typing of the variable tandem
repeat region of protein A (spa typing) [30].
PFGE
PFGE is still considered to be the reference
standard for typing MRSA isolates, and has been
demonstrated to be one of the most discriminative
typing methods for studying outbreaks and hos-
pital-to-hospital transmission. PFGE typing of
MRSA is based on digestion of puriﬁed chromo-
somal DNA with restriction enzyme SmaI, fol-
lowed by agarose gel electrophoresis. The PFGE
patterns are analysed with the Dice coefﬁcient
and unweighted pair-group matching analysis
(UPGMA) settings, according to the scheme of
Tenover et al. [31]. Signiﬁcant efforts have been
made to harmonise PFGE protocols and to estab-
lish a standardised nomenclature. However, these
efforts have proved only partially successful
when judged in terms of reproducibility, speed
and costs of analysis [32–34]. Because of the need
for strict adherence to standardised protocols,
common databases have been realised only at a
national level. At an international level, attempts
to produce a common nomenclature have not
been successful.
MLST
MLST is an excellent tool for investigating the
clonal evolution of MRSA. MLST is based on
sequence analysis of 0.5-kb fragments from seven
S. aureus housekeeping genes, i.e., arcC, aroE, glpF,
gmk, pta, tpi and yqiL. Different sequences are
assigned distinct alleles of each housekeeping
gene, and each isolate is deﬁned by the alleles of
the seven genes. This results in an allelic proﬁle or
sequence type (ST). For example, the so-called
Iberian clone has the MLST proﬁle 3-3-1-12-4-4–
16, which has been deﬁned as ST247 (http://
www.mlst.net). Currently, the nomenclature of
MRSA strains is based on the ST and the SCCmec
type; for example, ST247-MRSA-I is the Iberian
clone harbouring SCCmec type I. Clonal com-
plexes (CCs) can be deﬁned with the software
package BURST (based upon related sequence
types) to analyse evolutionary events (http://
www.mlst.net). S. aureus strains are grouped
within a single CC when ﬁve of the seven
housekeeping genes have identical sequences.
The ancestor of each CC is the ST with the largest
number of single-locus variants. Subgroup foun-
ders can be described as single-locus variants or
double-locus variants of a founder of a CC that
has become prevalent in a population, and that
may subsequently have diversiﬁed to produce its
own set of single-locus variants and double-locus
variants [35–38]. A disadvantage of MLST is that
it is rather laborious and time-consuming.
SCCmec typing
Four methods are currently available for the
characterisation of SCCmec. Oliveira and de Len-
castre [17] developed a multiplex PCR for SCCmec
types I–IV, in which mecA and six different loci on
SCCmec are detected (Fig. 1, Table 3) [17]. A
method has also been developed in which parts
of the structure of the mec complex (Table 1) and
the ccr genes are ampliﬁed by PCR (Table 3)
[7,39]. However, these methods gave different
results when the SCCmec type of the same MRSA
strain was characterised [13]. A real-time PCR has
also been developed to characterise SCCmec types
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I–IV on the basis of the mec complex and the ccr
genes [40]. Zhang et al. [41] developed a multiplex
PCR for the characterisation of SCCmec types I–V.
This method detects mecA and a single locus on
SCCmec. Since the existing methods each deter-
mine different structural properties of SCCmec, it
would be useful if a single universal method for
the classiﬁcation of this cassette was developed.
Chongtrakool et al. [14] have proposed a novel
classiﬁcation scheme for the nomenclature of
SCCmec, based on the ccr genes (indicated by a
number) and the mec complex (indicated by an
upper-case letter). Application of this nomencla-
ture results in SCCmec type 1A (type I), type 2A
(type II), type 3A (type III), type 2B (type IV) and
type 5C (type V). Differences in the J1 region and
the J2–J3 regions are then designated with num-
bers, e.g., SCCmec type 2B.2.1 (type IVb) (Table 2).
Finally, the ccr genes and the J regions are
numbered in chronological order according to
their discovery [14].
spa typing
Frenay et al. [42] developed a single-locus se-
quence typing method for S. aureus using the
sequences of the polymorphic region X of the
S. aureus protein A (spa) gene. This region consists
of a number of mainly 24-bp repeats, with its
diversity being attributed mainly to deletions and
duplications of the repeats and, more rarely, to
point mutations [43,44]. The main advantage of
spa typing over MLST is its simplicity, since it
involves sequencing only a single locus. The
discriminatory power of spa typing lies between
that of PFGE and MLST [45]. In contrast to MLST,
both molecular evolution and hospital outbreaks
of MRSA can be investigated with spa typing [46].
Another advantage of spa typing is that several
investigators can use ‘in-house’ sequencing plat-
forms and analyse the resulting sequence chro-
matograms using dedicated software. By this
means, decentralised typing is made accessible,
i.e., it is not available only in reference laborator-
ies. Comparability and a common nomenclature
with excellent quality of data are possible [47].
Two major nomenclature systems, described by
Koreen et al. [46] and Harmsen et al. [48], respect-
ively, are used worldwide. Unfortunately, this
difference in nomenclature systems makes com-
parison of published spa typing data difﬁcult. To
date, Ridom StaphType software (Ridom GmbH,
Wu¨rzburg, Germany) has been used widely for
the analysis of spa sequences in Europe. Individ-
ual laboratory typing data are synchronised via
the internet with the central spa server (http://
www.spaserver.ridom.de), which is curated by
the European SeqNet.org initiative (http://
www.seqnet.org) to ensure a universal nomen-
clature and public access to the typing data [48].
The current spa server database includes >1200
spa types, consisting of a combination of 100 spa
repeats from >13 000 isolates typed in 36 coun-
tries around Europe. Thus, this is one of the
largest sequence-based typing databases of S.
aureus. A further advantage is the possibility of
collecting spa typing data continuously for infec-
tion control purposes and of developing elec-
tronic early-warning algorithms for the automatic
detection of MRSA outbreaks in regions or hos-
pitals endemic for MRSA, but with heterogeneous
circulating spa types [49]. Because of the higher
discriminatory power, several spa types can be
found within one ST, as determined by MLST, but
they remain within an assigned clonal cluster
(Table 4) [37,50]. The implementation of the new
clustering algorithm based upon repeat patterns
(BURP) into StaphType makes a cluster analysis
based on spa typing data (spa clonal complexes)
possible, and future studies should investigate its
usefulness and compatibility with CCs estab-
lished by MLST.
THE MOLECULAR EVOLUTION OF
MRSA
MRSA emerged within 2 years of the introduction
of methicillin in 1959. These strains, which har-
boured SCCmec type I, were isolated in the UK.
During the 1960s, MRSA strains were isolated in
other European countries, and then during the
Table 3. Methods for SCCmec typing
SCCmec
Method of Ito et al. [7]
Method of Oliveira et al. [17]
Lociamec complex ccr genes
I B A1 ⁄B1 A, D
II A A2 ⁄B2 B, C, D
III A A3 ⁄B3 C, E, F
IV B A2 ⁄B2 D
V C C E
a Locus A (495 bp) is located downstream of the pls gene; locus B (284 bp) is internal
to the kdp operon; locus C (209 bp) is internal to the mecI gene; locus D (342 bp) is
internal to the dcs region; locus E (243 bp) is located in the region between
integrated plasmid pI258 and transposon Tn554; and locus F (414 bp) is located in
the region between Tn554 and the chromosomal right junction (orfX) [17]. Fig. 1
shows a schematic illustration of the different loci on SCCmec types I–V.
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1970s in other parts of the world, e.g., Australia,
Japan and the USA. Currently, MRSA is a major
cause of nosocomial infections worldwide. The
worldwide spread of MRSA is driven by the
dissemination of a number of clones with a
speciﬁc genetic background (Table 4) [30,37,51–
82].
Two opposing theories have previously been
suggested to describe the relationship between
the ﬁrst MRSA isolates and recent MRSA clones.
While the single-clone theory suggests that all
MRSA clones have a common ancestor, and that
SCCmec was introduced only once into S. aureus
[83], the multi-clone theory hypothesises that
SCCmec was introduced several times into differ-
ent S. aureus genetic lineages. The latter theory
has now been supported by several studies
[37,67,84,85].
Enright et al. [37] investigated 553 MSSA and
359 MRSA isolates, obtained between 1961 and
1999 from 20 countries, using both SCCmec typing
and MLST. Five clonal complexes were found
among the population, and strains with the same
ST harboured different SCCmec types (Table 4). It
was demonstrated that the major MRSA clones,
deﬁned as groups of isolates from more than one
country with the same ST and SCCmec type,
belonged to one of ﬁve clonal complexes (CC5, 8,
22, 30 and 45). As shown in Table 4, different
SCCmec types have been acquired by S. aureus
strains with different genetic backgrounds, and
this suggests that SCCmec was introduced several
times into different S. aureus genetic lineages.
Furthermore, ST8-MSSA in CC8 was shown to be
the ancestor of the ﬁrst MRSA strain isolated, i.e.,
ST250-MRSA-I, with ST250 differing from ST8 by
a point mutation in the yqiL gene. ST8-MSSA is a
common cause of epidemic MSSA disease, and
has acquired SCCmec types I, II and IV (Fig. 2).
Another clone that is related closely to ST250 is
ST247-MRSA-I, i.e., the Iberian clone. These STs
differ from each other by a single point mutation
at the gmk locus. ST247-MRSA-I (Fig. 2) is one of
the major MRSA clones isolated currently in
European hospitals.
Another major ST within CC8 is ST239-MRSA-
III, which corresponds to the Brazilian clone. This
clone has evolved by the transfer, through homol-
ogous recombination, of a 557-kb fragment of the
chromosome of ST30 into ST8-MRSA-III (Fig. 2)
Table 4. Overview of the major clones of methicillin-resistant Staphylcoccus aureus (MRSA)
Clone MLST proﬁle ST CC SCCmec spa typea Geographical spreadb
Archaic 3-3-1-1-4-4-16 250 8 I t008, t009, t194 Ast, Den, Ger, Swi, Uga, UK, USA
Southern Germany 1-4-1-4-12-24-29 228 5 I t001, t023, t041, t188,
t201
Bel, Den, Ger, Ita, Slo, Spa, Swi
UK EMRSA-3 1-4-1-4-12-1-10 5 5 I t001, t002, t003, t010,
t045, t053, t062, t105,
t178, t179, t187, t214,
t311, t319, t389, t443
Arg, Nor, Pol, Slo, UK
Iberian 3-3-1-12-4-4-16 247 8 I t008, t051, t052, t054,
t200
Bel, Cro, Cze, Den, Fin, Fra, Ger, Ita, Net, Pol, Por,
Slo, Spa, Swe, Swi, UK, USA
Irish-1 3-3-1-1-4-4-3 8 8 II t008, t024, t064, t190,
t206, t211
Ast, Ire, UK, USA
New York ⁄ Japan 1-4-1-4-12-1-10 5 5 II t001, t002, t003, t010,
t045, t053, t062, t105,
t178, t179, t187, t214,
t311, t319, t389, t443
Ast, Bel, Can, Den, Fin, Fra, Ger, Ire, Jap, Kor,
Mex, Sin, Swe, Uru, UK, USA
UK EMRSA-16 2-2-2-2-3-3-2 36 36 II t018, t253, t418, t419 Ast, Bel, Can, Den, Fin, Gre, Ire, Mex, Nor, Spa,
Swe, Swi, UK, USA
Brazilian ⁄Hungarian 2-3-1-1-4-4-3 239 8 III t030, t037, t234, t387,
t388
Alg, Arg, Ast, Aus, Bra, Chi, Chn, Cze, Fin, Ger,
Gre, Ind, Ids, Kor, Mon, Net, Pol, Por, Sin, Slo,
Spa, Sri, Swe, Tha, UK, Uru, USA, Vie
Berlin 10-14-8-6-10-3-2 45 45 IV t004, t015, t026, t031,
t038, t050, t065, t204,
t230, t390
Arm, Ast, Bel, Fin, Ger, Hun, Net, Nor, Spa,
Swe, Swi, USA
Paediatric 1-4-1-4-12-1-10 5 5 IV t001, t002, t003, t010,
t045, t053, t062, t105,
t178, t179, t187, t214,
t311, t319, t389, t443
Alg, Arg, Ast, Bra, Col, Den, Fra, Kor, Nor, Pol,
Por, Spa, Swe, Uru, UK, USA
UK EMRSA-2 ⁄ -6 3-3-1-1-4-4-3 8 8 IV t008, t024, t064, t190,
t206, t211
Ast, Bel, Fin, Fra, Ger, Ire, Net, Nor, Tai,
UK, USA
UK EMRSA-15 7-6-1-5-8-8-6 22 22 IV t005, t022, t032, t223,
t309, t310, t417, t420
Ast, Bel, Cze, Den, Ger, Ire, Kuw, NZ,
Nor, Por, Sin, Spa, Swe, UK
aspa types according to spa server (most prevalent spa type in bold).
bAlg, Algeria; Arg, Argentina; Arm, Armenia; Ast, Australia; Aus, Austria; Bel, Belgium; Bra, Brazil; Can, Canada; Chi, Chile; Chn, China; Col, Colombia; Cro, Croatia; Cze,
Czech Republic; Den, Denmark; Fin, Finland; Fra, France; Ger, Germany; Gre, Greece; Hun, Hungary; Ind, India; Ids, Indonesia; Ire, Ireland; Ita, Italy; Jap, Japan; Kor, Korea;
Kuw, Kuwait; Mex, Mexico; Mon, Mongolia; Net, The Netherlands; NZ, New Zealand; Nor, Norway; Pol, Poland; Por, Portugal; Sin, Singapore; Slo, Slovenia; Sri, Sri Lanka;
Spa, Spain; Swe, Sweden; Swi, Switzerland; Tai, Taiwan; Tha, Thailand; Uga, Uganda; Uru, Uruguay; Vie, Vietnam.
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[50]. It was further shown that CC5, 22, 30 and 45
were all derived from epidemic MSSA lineages
that have acquired SCCmec, since they differed
from each other, and from ST8, at six or seven loci
(Table 4). Furthermore, MLST analyses showed
that some of the ﬁrst vancomycin-intermediate
S. aureus isolates have emerged from ST5-MRSA-
II, a pandemic MRSA clone known as the New
York ⁄ Japan clone [37]. It has also been shown that
multiple lineages of S. aureus harbour different
SCCmec types among hospitalised patients in
Australia [86].
A study of 147 MRSA isolates with geograph-
ically diverse origins indicated that MRSA has
emerged at least 20 times following acquisition of
SCCmec, and that the acquisition of SCCmec by
MSSA was four-fold more common than the
replacement of one SCCmec with another. Inter-
estingly, SCCmec type IV was found in twice as
many MRSA clones as other SCCmec types,
suggesting that most clones arise by acquisition
of SCCmec type IV by S. aureus [87]. This is
probably a result of the smaller size of SCCmec
type IV compared with other SCCmec types,
which may facilitate transfer of the cassette
among staphylococcal species [88]. Furthermore,
it has been shown that MRSA strains that belong
to the major CCs (1, 5, 8, 22, 30 and 45) are easier
to transform with mecA-expressing plasmids than
are strains belonging to minor CCs. This indicates
that the genetic background of S. aureus may be
important for the stability of SCCmec [89].
Besides the major clones shown in Table 4,
MRSA strains are also isolated in single hospitals
(minor clones) or from single patients (sporadic
isolates) [30]. Two studies have been published in
which clonal evolution within a single hospital
was described. ST30-MRSA-IV was present in a
Mexican hospital between 1997 and 2000, but this
clone was replaced by ST5-MRSA-II during 2001,
with the latter clone predominating in 2002 [57].
Similarly, a study in Spain showed that ST247-
MRSA-I was replaced by ST36-MRSA-II between
1998 and 2002 [56]. Although most MRSA strains
are isolated in hospitals, community-acquired
(CA) strains have now emerged.
THE EMERGENCE OF CA-MRSA
The worldwide emergence of CA-MRSA is a
threat to individuals in both the community and
the hospital environment, since these strains are
known to be more virulent than hospital-acquired
(HA)-MRSA strains [90,91]. Furthermore, CA-
MRSA strains have started to replace HA-MRSA
in healthcare settings [92,93].
Although at least eight deﬁnitions for CA-
MRSA exist [94,95], a general and international
agreement has now been reached on a universal
deﬁnition of CA-MRSA, i.e., strains isolated in an
Fig. 2. Evolutionary origin of the major methicillin-resistant Staphylococcus aureus (MRSA) clones and the possible
relationship between community-acquired (CA)-MRSA and hospital-acquired (HA)-MRSA. The arrows indicate either the
acquisition of SCCmec, a change of SCCmec, a change of sequence type (ST), or the acquisition of the genes encoding
Panton–Valentine leukocidin (PVL). The grey-shaded circles represent the MRSA clones from CC30, while the white circles
represent the MRSA clones from CC8. ST239-MRSA-III from CC8 has evolved by the transfer of a 557-kb fragment from the
chromosome of ST30 into an ST8 background [37,88,112]. MSSA, methicillin-sensitive Staphylococcus aureus.
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outpatient setting, or from patients within 48 h of
hospital admission. Furthermore, such patients
must have no history of MRSA infection or
colonisation, and no history in the previous year
of either hospitalisation, admission to a nursing
home, dialysis or surgery. Moreover, the patient
should not have permanent indwelling catheters
or medical devices that pass through the skin.
The ﬁrst CA-MRSA strain was reported in
Western Australia during 1993 in patients from
remote communities with no known risk-factors
for MRSA colonisation [96]. CA-MRSA is both
phenotypically and genotypically distinct from
HA-MRSA. In contrast to HA-MRSA, CA-MRSA
strains are generally susceptible to antibiotics
other than b-lactams. PFGE analyses have shown
that CA-MRSA strains belong to clonal types
unrelated to clones isolated in hospitals [97,98].
Furthermore, MLST has shown that CA-MRSA
has greater clonal diversity than HA-MRSA
[37,39]. Although CA-MRSA strains mainly har-
bour SCCmec types IV or V [5,8,9], two reports
have described some CA-MRSA strains harbour-
ing SCCmec types I, II or III [52,99], while another
report described HA-MRSA strains with SCCmec
type IV [100]. This shows that the distinction
between CA-MRSA and HA-MRSA based on the
SCCmec type is beginning to blur.
There are conﬂicting reports as to whether a
relationship exists between SCCmec type IV and
production of Panton–Valentine leukocidin
(PVL). PVL is a S. aureus-speciﬁc exotoxin, enco-
ded by two co-transcribed genes designated lukF-
PV and lukS-PV, and is associated with skin and
soft-tissue infections and severe necrotising pneu-
monia [27,101]. Vandenesch et al. [27] showed
that CA-MRSA was characterised by SCCmec type
IV, and that PVL was a stable genetic marker for
CA-MRSA. The relationship among CA-MRSA,
SCCmec type IV and PVL was conﬁrmed by a
study in the USA by Shukla et al. [58]. However,
O’Brien et al. [59] did not ﬁnd a relationship
between CA-MRSA, SCCmec type IV and PVL in
Australia. Further studies showed PVL-positive
CA-MRSA strains harbouring SCCmec types I and
III in The Netherlands [99] and PVL-positive HA-
MRSA strains in Algeria [73]. In general, <5% of
MRSA strains harbouring SCCmec types I–III
carry PVL, and 40–90% of MRSA strains that
harbour SCCmec type IV also carry PVL [102].
Further studies are needed to investigate the
possible relationship between SCCmec type IV
(and type V) and PVL in CA-MRSA strains.
Recently, Mu¨ller-Premru et al. [103] described
the ﬁrst detection of PVL in MRSA with ST5 (spa
t002), and CA-MRSA with ST152 (spa t454),
associated with a clinically signiﬁcant outbreak
of infections among members of a football team in
Slovenia. The emergence of PVL in MRSA with
ST5 (spa t002) is of particular concern because of
its epidemic potential [103].
Worldwide, CA-MRSA strains differ in their
SCCmec type, PFGE pattern, and MLST and spa
proﬁles, with ST30 (spa t012, t018, t019, t021, t138,
t268, t276, t318, t338, t391) in Australian and South
American isolates, ST80 (spa t044) in European
and Middle Eastern isolates, and ST1 (spa t127,
t128, t174, t176, t386, t558), ST8 (spa t008, t024,
t064, t190, t206, t211) and ST59 (spa t199, t216,
t444) in USA isolates [27,104]. Although many
CA-MRSA strains harbour SCCmec type IV, CA-
MRSA strains with the ST80 genetic background
harbour SCCmec type IVc, and CA-MRSA strains
with ST1 harbour SCCmec type IVa [105]. Fur-
thermore, European CA-MRSA strains carry the
far1 gene, encoding fusidic acid resistance, and
have a unique spa type. This European CA-MRSA
clone has spread through Belgium, Finland,
France, Germany, Norway, Scotland, Sweden
and Yugoslavia [65,106–108].
CA-MRSA strains harbouring SCCmec type V
are present among isolates from Australia with
ST5, ST8, ST45, ST59, ST152, ST573 and ST577,
from Taiwan with ST59, from Finland with ST8
and ST27, from Uruguay with ST45, from
Singapore with ST1, ST7, ST8, ST45, ST59,
ST88, ST188, ST524 and ST573, from France with
ST377, and from Kosovo with ST152 [18,69–
72,81,86,109,110]. These studies showed that
CA-MRSA strains harbouring SCCmec type V
have a diverse genetic background.
It is unclear whether SCCmec elements in CA-
MRSA have been acquired by MSSA strains in the
community, or whether they have been derived
from HA-MRSA. Okuma et al. [39] showed that
CA-MRSA strains represent novel acquisitions of
SCCmec type IV in the community. Another study
raised the possibility that some CA-MRSA strains
may originate in hospitals, since several similar-
ities were found between CA-MRSA and HA-
MRSA strains [111]. A recent study has suggested
that an HA-MRSA and a CA-MRSA clone have a
common ancestor. During the 1950s, a penicillin-
resistant S. aureus clone (phage type 80 ⁄ 81)
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emerged worldwide in hospitals and the commu-
nity, but was largely eliminated following the
introduction of penicillinase-resistant b-lactam
antibiotics during the 1960s. It has been shown
that this clone was ST30-MSSA and harboured
PVL. The clone re-emerged and acquired SCCmec
type IV to become the main CA-MRSA clone
found in Australia (ST30-MRSA-IV). In addition,
ST30-MSSA has also acquired SCCmec type II,
possibly via several intermediate steps, such as
the acquisition of SCCmec type IV, to become
ST36-MRSA-II, the pandemic EMRSA-16 clone
(Fig. 2) [112].
PREVALENCE AND RISK-FACTORS
A high prevalence of MRSA in hospitals has been
associated with increased patient mortality and
higher healthcare costs. The SENTRY antimicro-
bial surveillance programme found that the pre-
valence of MRSA in hospitals between 1997 and
1999 was 22.4% in Australia, 66.8% in Japan,
34.9% in Latin America, 40.4% in South America,
32.4% in the USA and 26.3% in Europe [113,114].
The prevalence of MRSA in Europe varies among
countries; e.g., the prevalence of MRSA in the
northern European countries (c. 0.6% in Scandi-
navian countries and The Netherlands) is signiﬁ-
cantly lower than in other European countries (up
to 44.7%). The low prevalence of MRSA in The
Netherlands and Scandinavia has been attributed
to a low antibiotic selection pressure and screen-
ing of ‘high-risk’ patients for MRSA before or at
the time of admission to a hospital (‘search-and-
destroy’ policy) [115]. More effective disinfection
procedures and hand hygiene guidelines could, in
part, help to prevent the spread of MRSA in the
hospital environment [116]. Strict implementation
of the above rules in Denmark, beginning at a
time when the prevalence of MRSA was as high
as 30%, have decreased the MRSA prevalence to
<1% [117]. Risk-factors for MRSA colonisation
include previous exposure to one or several
antibiotics, prolonged duration of therapy, stay
in an intensive care or burns unit, severe under-
lying illness, invasive procedures, surgical
wounds or burns, and contact with patients
colonised with MRSA [118–123].
The prevalence of CA-MRSA is currently low
worldwide, but appears to be increasing [91,95].
The prevalence of CA-MRSA is <0.5%, but HA-
MRSA strains are also circulating in the commu-
nity [124–126]. Salgado et al. [95] performed a
global analysis of 57 studies on CA-MRSA pre-
valence among hospitalised patients and individ-
uals in the community, and found that most
individuals with CA-MRSA had at least one risk-
factor for MRSA. This study suggested that the
prevalence of CA-MRSA among individuals with-
out risk-factors is 0.24% [95]. A recent study
showed that the prevalence of CA-MRSA in
Europe is 0.03–1.5% [115]. Among >13 275 entries
in the spa database, spa type t044 (ST80), which is
highly associated with PVL, accounted for 685
(5.16%) isolates and was the ﬁfth most frequent
spa type. However, more frequent typing of CA-
MRSA strains with a higher rate of infection may
contribute to over-representation in this database.
The higher rates of CA-MRSA colonisation among
Australian aboriginals (76%) or native Americans
(62%) are probably associated with risk-factors
for spread in the community, e.g., skin infections
and the use of broad-spectrum antibiotics
[97,127].
A number of risk-factors associated with CA-
MRSA colonisation have been identiﬁed. These
include gastrointestinal disease, intravenous drug
use, direct contact with an individual who has a
skin infection with CA-MRSA, indirect contact
with contaminated objects, such as shared soap
bars and towels in sport facilities and jails, and
close contact among military recruits. Further-
more, recent medication, other than antibiotics,
also seems to be a risk-factor for CA-MRSA
colonisation [90,128–130]. Nevertheless, further
studies to investigate the true prevalence of CA-
MRSA and the risk-factors for CA-MRSA coloni-
sation are required.
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